Positive Impact of Eculizumab Therapy on Surgery for Budd- Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Longterm History of Thrombosis

Iglesia, Silvia de la; Luzardo, Hugo; Lemes, Angelina; Torres, Melissa; Gómez‐Casares, María Teresa; Cruz, Naylen; Molero, Teresa

doi:10.4081/hr.2016.6562

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite reports indicating potential postoperative risks in laparoscopic surgeries, such as infection [55], pain [56], pruritus [57], or serohematic drainage [58], and more pronounced risks in open abdominal surgical wounds [59][60][61], the application of NTP in both types of surgeries demonstrated the absence of infection, pain, itching, erythema, or purulent discharge. Notably, no cases of sepsis were reported.…”

Section: Discussionmentioning

confidence: 88%

“…Despite reports indicating potential postoperative risks in laparoscopic surgeries, such as infection [55], pain [56], pruritus [57], or serohematic drainage [58], and more The effectiveness of the NTP procedure was evaluated using the χ 2 method, and a result of 4.28 was obtained. This value indicated the effectiveness of NTP at promoting faster wound closure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing Non-Thermal Plasma to Supercharge Recovery in Abdominal Surgeries: A Pilot Study

Rodríguez-Méndez,

López-Callejas,

Mercado-Cabrera

et al. 2024

JCM

View full text Add to dashboard Cite

(1) Background: This study aims to evaluate the efficacy and safety of non-thermal plasma (NTP) therapy in accelerating wound healing in patients who have undergone laparoscopic and open surgeries. (2) Methods: NTP was applied using a needle-type reactor with an irradiance of 0.5 W/cm2 on the surgical wounds of fifty patients after obtaining informed consent. Three NTP treatments, each lasting three minutes, were administered hourly. (3) Results: The pilot study showed that NTP-treated surgical wounds healed completely without any signs of infection, dehiscence, pain, or itching. Notably, patients reported minimal pain after the NTP treatment. Visual assessments conducted twenty-four hours after surgery revealed no redness or fluid discharge. Comparisons with traditionally sutured wounds indicated that NTP-treated wounds healed at a rate equivalent to seven days. (4) Conclusions: The application of NTP in laparoscopic and open wounds proved safe and effective, expediting the wound healing process and eliminating clinical risks post-surgery. Significantly, NTP facilitated a healing rate within twenty-four hours, equivalent to seven days for suture-treated wounds, significantly reducing the hospitalization time to a single day. These findings highlight the potential of NTP to be a transformative approach for promoting postoperative recovery.

show abstract

Section: Discussionmentioning

confidence: 88%

“…Despite reports indicating potential postoperative risks in laparoscopic surgeries, such as infection [55], pain [56], pruritus [57], or serohematic drainage [58], and more The effectiveness of the NTP procedure was evaluated using the χ 2 method, and a result of 4.28 was obtained. This value indicated the effectiveness of NTP at promoting faster wound closure.…”

Section: Discussionmentioning

confidence: 99%

Harnessing Non-Thermal Plasma to Supercharge Recovery in Abdominal Surgeries: A Pilot Study

Rodríguez-Méndez,

López-Callejas,

Mercado-Cabrera

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…The phenotype of the disease is red blood cell hemolysis to a severe degree, which often requires blood transfusions, and frequently thrombosis ( Hill et al, 2013 ). Particularly serious are those developing in the gastrointestinal area, such as the Budd-Chiari ( De-la-Iglesia et al, 2016 ). The details of treatment of PNH are given below.…”

Section: Role Of Complement In Disease Pathophysiologymentioning

confidence: 99%

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

Garred

Tenner

Mollnes

2021

Pharmacological Reviews

123

View full text Add to dashboard Cite

The complement system was discovered at the end of the 19th century as a heat-labile plasma component that “complemented” the antibodies in killing microbes, hence the name “complement.” Complement is also part of the innate immune system, protecting the host by recognition of pathogen-associated molecular patterns. However, complement is multifunctional far beyond infectious defense. It contributes to organ development, such as sculpting neuron synapses, promoting tissue regeneration and repair, and rapidly engaging and synergizing with a number of processes, including hemostasis leading to thromboinflammation. Complement is a double-edged sword. Although it usually protects the host, it may cause tissue damage when dysregulated or overactivated, such as in the systemic inflammatory reaction seen in trauma and sepsis and severe coronavirus disease 2019 (COVID-19). Damage-associated molecular patterns generated during ischemia-reperfusion injuries (myocardial infarction, stroke, and transplant dysfunction) and in chronic neurologic and rheumatic disease activate complement, thereby increasing damaging inflammation. Despite the long list of diseases with potential for ameliorating complement modulation, only a few rare diseases are approved for clinical treatment targeting complement. Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorders. Rare diseases, unfortunately, preclude robust clinical trials. The increasing evidence for complement as a pathogenetic driver in many more common diseases suggests an opportunity for future complement therapy, which, however, requires robust clinical trials; one ongoing example is COVID-19 disease. The current review aims to discuss complement in disease pathogenesis and discuss future pharmacological strategies to treat these diseases with complement-targeted therapies. Significance Statement The complement system is the host’s defense friend by protecting it from invading pathogens, promoting tissue repair, and maintaining homeostasis. Complement is a double-edged sword, since when dysregulated or overactivated it becomes the host’s enemy, leading to tissue damage, organ failure, and, in worst case, death. A number of acute and chronic diseases are candidates for pharmacological treatment to avoid complement-dependent damage, ranging from the well established treatment for rare diseases to possible future treatment of large patient groups like the pandemic coronavirus disease 2019.

show abstract

Eculizumab

2016

Reactions Weekly

View full text Add to dashboard Cite

Positive Impact of Eculizumab Therapy on Surgery for Budd- Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Longterm History of Thrombosis

Cited by 5 publications

References 18 publications

Harnessing Non-Thermal Plasma to Supercharge Recovery in Abdominal Surgeries: A Pilot Study

Harnessing Non-Thermal Plasma to Supercharge Recovery in Abdominal Surgeries: A Pilot Study

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

Eculizumab

Contact Info

Product

Resources

About